Advertisement

Drugs

, Volume 38, Issue 6, pp 855–862 | Cite as

Treatment of Patients with Chronic Fatigue Syndrome

  • Nelson M. Gantz
  • Gary P. Holmes
Leading Article

Keywords

Fibromyalgia Chronic Fatigue Syndrome Acyclovir Acquire Immune Deficiency Syndrome Chronic Fatigue Syndrome Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Acheson ED. The clinical syndrome variously called benign myalgic encephalomyelitis, Iceland disease and epidemic neuromyasthenia. American Journal of Medicine 26: 569–595, 1959PubMedCrossRefGoogle Scholar
  2. Adolphe AB. Chronic fatigue syndrome: possible effective treatment with nifedipine. American Journal of Medicine 85: 892, 1988PubMedCrossRefGoogle Scholar
  3. Anderson JA, Chai H, Claman HV. Candidiasis hypersensitivity syndrome. Journal of Allergy and Clinical Immunology 78: 271–273, 1986CrossRefGoogle Scholar
  4. Andersson J, Britton S, Ernberg I, Andersson U, Henle W, et al. Effect of acyclovir on infectious mononucleosis: a double-blind, placebo-controlled study. Journal of Infectious Diseases 153: 283–290, 1986PubMedCrossRefGoogle Scholar
  5. Andersson J, Ernberg I. Management of Epstein-Barr virus infections. American Journal of Medicine 85 (Suppl. 2A): 107–115, 1988PubMedGoogle Scholar
  6. Beard G. Neurasthenia or nervous exhaustion. Boston Medical and Surgical Journal 3 (new series): 217–220, 1869CrossRefGoogle Scholar
  7. Behan PO, Behan WMH. Postviral fatigue syndrome. CRC Critical Reviews in Neurobiology 4: 157–178, 1988PubMedGoogle Scholar
  8. Behan PO, Behan WMH, Bell EJ. The postviral fatigue syndrome: an analysis of the findings in 50 cases. Journal of Infection 10: 211–222, 1985PubMedCrossRefGoogle Scholar
  9. Bennett RM, Gatter RA, Campbell SM, Andrews RP, Clark SR, et al. A comparison of cyclobenzaprine and placebo in the management of fibrositis: a double-blind controlled study. Arthritis and Rheumatism 31: 1535–1542, 1988PubMedCrossRefGoogle Scholar
  10. Buchwald D, Goldenberg DL, Sullivan JL, Komaroff AL. The ‘chronic active Epstein-Barr virus infection’ syndrome and primary fibromyalgia. Arthritis and Rheumatism 30: 1132–1136, 1987PubMedCrossRefGoogle Scholar
  11. Caligiuri M, Murray C, Buchwald D, Levine H, Cheney P, et al. Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. Journal of Immunology 139: 3306–3313, 1987Google Scholar
  12. Dale JK, Straus SE, Ablashi DV, Salahuddin ZS, Gallo RC, et al. The Inoue-Melnick virus, human herpesvirus type 6, and the chronic fatigue syndrome. Annals of Internal Medicine 110: 92–93, 1989PubMedGoogle Scholar
  13. Dillon MJ, Marshall WC, Dudgeon JA, Steigman AJ. Epidemic neuromyasthenia: outbreak among nurses at a children’s hospital. British Medical Journal 1: 301–305, 1974PubMedCrossRefGoogle Scholar
  14. DuBois RE. Gamma globulin therapy for chronic mononucleosis syndrome. AIDS Research 2: S191–S195, 1986PubMedGoogle Scholar
  15. DuBois RE, Seeley J, Brus I, Sakamoto K, Ballow M, et al. Chronic mononucleosis syndrome. Southern Medical Journal 77: 1376–1382, 1984PubMedCrossRefGoogle Scholar
  16. Galpine JF, Brady C. Benign myalgic encephalomyelitis. Lancet 1: 757, 1957CrossRefGoogle Scholar
  17. Gilliam AG. Epidemiologic study of epidemic diagnosed as poliomyelitis, occurring among personnel of Los Angeles County General Hospital during the summer of 1934. US Public Health Service, Division of Infectious Diseases, Institute of Health, Bulletin 240, pp. 1–90, 1938Google Scholar
  18. Glaser R, Kiecolt-Glaser K. Stress-associated depression in cellular immunity: implications for acquired immune deficiency syndrome (AIDS). Brain, Behavior and Immunity 1: 107–112, 1987CrossRefGoogle Scholar
  19. Goldenberg DL, Felson DT, Dinerman H. A randomized controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism 29: 1371–1377, 1986PubMedCrossRefGoogle Scholar
  20. Goldstein JA. Cimetidine, ranitidine and Epstein-Barr virus infection. Annals of Internal Medicine 105: 139, 1986PubMedGoogle Scholar
  21. Henderson DA, Shelokov A. Epidemic neuromyasthenia: clinical syndrome? New England Journal of Medicine 260: 757–764; 814–818, 1959PubMedCrossRefGoogle Scholar
  22. Holmes GP, Kaplan JE, Gantz NM, Komaroff AL, Schonberger LB, et al. Chronic fatigue syndrome: a working case definition. Annals of Internal Medicine 108: 387–389, 1988PubMedGoogle Scholar
  23. Jones JF, Ray CG, Minnich LL, Hicks J, Kibler R, et al. Evidence for active Epstein-Barr virus infection in patients with persistent unexplained illness: elevated anti-early antigen antibodies. Annals of Internal Medicine 102: 1–7, 1985PubMedGoogle Scholar
  24. Jones JF, Straus SE. Chronic Epstein-Barr virus infection. Annual Review of Medicine 38: 195–209, 1987PubMedCrossRefGoogle Scholar
  25. Komaroff AL, Geiger AM, Wormsely S. IgG subclass deficiencies in chronic fatigue syndrome. Lancet 1: 1288–1289, 1988PubMedCrossRefGoogle Scholar
  26. Komaroff AL, Straus SE, Gantz NM, Jones JF. The chronic fatigue syndrome. Annals of Internal Medicine 110: 407–408, 1989PubMedGoogle Scholar
  27. Kruesi MJP, Dale JK, Straus SE. Psychiatric diagnoses in patients who have chronic fatigue syndrome. Journal of Clinical Psychiatry 50: 53–56, 1989PubMedGoogle Scholar
  28. McEvedy CP, Beard AW. Royal Free epidemic of 1955: a reconsideration. British Medical Journal 1: 7–11, 1970PubMedCrossRefGoogle Scholar
  29. Medical Staff of the Royal Free Hospital. An outbreak of encephalomyelitis in the Royal Free Hospital Group, London, in 1955. British Medical Journal 2: 895–904, 1957CrossRefGoogle Scholar
  30. Meth RJ. Chronic fatigue. Correspondence. Journal of the American Medical Association 261: 696–697, 1989CrossRefGoogle Scholar
  31. Pagano JS, Sixbey JW, Lin J-C. Acyclovir and Epstein-Barr virus infection. Journal of Antimicrobial Chemotherapy 12: B113–B121, 1983Google Scholar
  32. Poskanzer DC, Henderson DA, Kunkle EC, Kalter SS, Clement WB, et al. Epidemic neuromyasthenia: an outbreak in Punta Gorda, Florida. New England Journal of Medicine 257: 356, 1957PubMedCrossRefGoogle Scholar
  33. Quinn JP, Venezio FR. Ketoconazole and the yeast connection. Journal of the American Medical Association 255: 3250, 1986PubMedCrossRefGoogle Scholar
  34. Rabkin J, Quitkin F, Harrison W, Tricamo E, McGrath P. Adverse reactions to monoamine oxidase inhibitors. Part I: a comparative study. Journal of Clinical Psychopharmacology 4: 270–278, 1984Google Scholar
  35. Rabkin J, Quitkin FM, McGrath P, Harrison W, Tricamo E. Adverse reactions to monoamine oxidase inhibitors. Part II: treatment correlates and clinical management. Journal of Clinical Psychopharmacology 5: 2–9, 1985Google Scholar
  36. Read R, Spickett G, Harvey J, Edwards AJ, Larson HE. IgGl subclass deficiency in patients with the chronic fatigue syndrome. Correspondence. Lancet 1: 241–242, 1988CrossRefGoogle Scholar
  37. Renfro L, Feder HM, Lane TJ, Manu P, Matthews DA. Yeast connection among 100 patients with chronic fatigue. American Journal of Medicine 86: 165–168, 1989PubMedCrossRefGoogle Scholar
  38. Rosenberg GA, Appenzeller O. Amantadine, fatigue and multiple sclerosis. Archives of Neurology 45: 1104–1106, 1988PubMedCrossRefGoogle Scholar
  39. Shelokov A, Habel K, Verder E, et al. Epidemic neuromyasthenia: an outbreak of poliomyelitis-like illness in student nurses. New England Journal of Medicine 257: 345–355, 1957PubMedCrossRefGoogle Scholar
  40. Sigurdsson B, Gudmundsson KR. Clinical findings six years after outbreak of Akureyri disease. Lancet 1: 766–767, 1956CrossRefGoogle Scholar
  41. Sigurdsson B, Sigurjonsson J, Sigurdsson JH, Thorkelsson J, Gudmundsson KR. A disease epidemic in Iceland simulating poliomyelitis. American Journal of Hygiene 52: 222–238, 1950PubMedGoogle Scholar
  42. Straus SE. The chronic mononucleosis syndrome. Journal of Infectious Diseases 157: 405–412, 1988PubMedCrossRefGoogle Scholar
  43. Straus SE, Dale JK, Tobi M, Lawley T, Preble O, et al. Acyclovir treatment of the chronic fatigue syndrome: lack of efficacy in a placebo-controlled trial. New England Journal of Medicine 319: 1692–1698, 1988aPubMedCrossRefGoogle Scholar
  44. Straus SE, Dale JK, Wright R, Metcalfe DD. Allergy and the chronic fatigue syndrome. Journal of Allergy and Clinical Immunology 81: 791–795, 1988bPubMedCrossRefGoogle Scholar
  45. Straus SE, Tosato G, Armstrong G, Lawley T, Preble OT, et al. Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection. Annals of Internal Medicine 102: 7–16, 1985PubMedGoogle Scholar
  46. Taerk GS, Toner BB, Salit IE, Garfinkel PE, Ozersky S. Depression in patients with neuromyasthenia (benign myalgic encephalomyelitis). International Journal of Psychiatry in Medicine 17:49–56, 1987PubMedCrossRefGoogle Scholar
  47. Tobi M, Morag A, Ravid Z, Chowers I, Feldman-Weiss V, et al. Prolonged atypical illness associated with serologic evidence of persistent Epstein-Barr virus infection. Lancet 1: 61–64, 1982PubMedCrossRefGoogle Scholar
  48. Tollefson GD. Monoamine oxidase inhibitors: a review. Journal of Clinical Psychiatry 44: 280–288, 1983PubMedGoogle Scholar
  49. Tucker GJ. Psychiatric disorders in medical practice. In Wyngaarden JB & Smith Jr LH (Eds) Cecil textbook of medicine, 18th ed., pp. 2091–2100, WB Saunders Company, Philadelphia, 1988Google Scholar
  50. White DN, Burtch RB. Iceland disease: new infection simulating acute anterior poliomyelitis. Neurology 4: 506–516, 1954PubMedCrossRefGoogle Scholar
  51. Yousef GE, Bell EJ, Mann GP, Murugesan V, Smith DG, et al. Chronic enterovirus infection in patients with postviral fatigue syndrome. Lancet 1: 146–150, 1988PubMedCrossRefGoogle Scholar
  52. Zimmerman MH, Weber E. Candida and ‘20th Century disease’. Canadian Medical Association Journal 133: 965–966, 1986Google Scholar

Copyright information

© ADIS Press Limited 1989

Authors and Affiliations

  • Nelson M. Gantz
    • 1
    • 2
  • Gary P. Holmes
    • 1
  1. 1.Department of Medicine, Division of Infectious DiseasesUniversity of Massachusetts Medical CenterWorcesterUSA
  2. 2.Division of Viral Diseases, Public Health Service, United States Department of Health and Human ServicesAtlantaUSA

Personalised recommendations